Advertisement

Wirkung des selektiven Alpha1-Blockers Urapidil auf die Hämodynamik von Patienten mit chronischer Herzinsuffizienz ohne arterielle Hypertonie

  • S. Silber
  • F. Hany
  • M. Weber
  • K. Theisen
  • H. Jahrmärker
Conference paper

Zusammenfassung

Bei Patienten mit fortgeschrittener Herzinsuffizienz findet das Prinzip der medikamentösen Entlastung mit Vasodilatatoren als „dritte Säule“ neben Digitalis und Diuretika zunehmend Anwendung [6, 7, 10, 18, 30, 32, 38, 55]. Hierzu kommen entweder überwiegend arteriell angreifende, d. h. die Nachlast senkende Vasodilatatoren (z. B. Minoxidil, Hydralazin, Nifedipin, Phentolamin) oder Nitrate, die über eine Venodilatation die Vorlast reduzieren, in Betracht. Eine Mittelstellung nehmen Substanzen wie Natriumnitroprussid und Captopril ein, die sowohl im arteriellen als auch im venösen Bereich dilatierend wirken.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Arnold SB, Williams RL, Ports TA, Baughman RA, Benet LZ, Parmley WW, Chatterjee K (1979) Attenuation of prazosin effect on cardiac output in chronic heart failure. Ann Int Med 91: 345–349PubMedGoogle Scholar
  2. 2.
    Awan NA, Lee G, DeMaria AN, Mason DT (1981) Ambulatory prazosin treatment of chronic congestive heart failure: Development of late tolerance reversible by higher dosage and interrupted substituation therapy. Am Heart J 101: 541–547PubMedCrossRefGoogle Scholar
  3. 3.
    Bailar JC, Louis TA, Lavori PW, Polansky M (1984) Studies without internal controls. N Engl J Med 311: 156–162PubMedCrossRefGoogle Scholar
  4. 4.
    Barankay A, Göb E, Richter JA (1981) Treatment of hypertension in coronary bypass surgery. Clinical experience with urapidil. Arzneimittelforsch 31: 849–852PubMedGoogle Scholar
  5. 5.
    Beiz GG (1984) Die Wirkungen von Urapidil auf das kardiovaskuläre System des Menschen. Symposium: Urapidil bei Hypertonie und Herzinsuffizienz. IX. Europäischer Kongress für Kardiologie, 11. Juli, DüsseldorfGoogle Scholar
  6. 6.
    Bertel O (1983) Behandlung der Herzinsuffizienz mit Vasodilatatoren. Fortschr Med 101: 1437–1439PubMedGoogle Scholar
  7. 7.
    Braunwald E (1984) Vasodilator therapy of heart failure. New Engl J Med 310: 459–461PubMedCrossRefGoogle Scholar
  8. 8.
    Bruckschen EG, Henze F, Michael G (1978) Clinical trials of urapidil. Review of human pharmacological studies with a summary of a multicenter study. Arzneimittelforsch 28: 1176–1184PubMedGoogle Scholar
  9. 9.
    Bruckschen EG, Haerlin R (1980) Hochdrucktherapie mit Ebrantil. Therapiewoche 30: 7850–7851Google Scholar
  10. 10.
    Cohn JN, Franciosa JA (1977) Vasodilator therapy of cardiac failure. New Engl J Med 297: 228–258Google Scholar
  11. 11.
    Collins P, Sheridan D (1985) Improvement in angina pectoris with alpha adrenoceptor blockade. Br Heart J 53: 488–492PubMedCrossRefGoogle Scholar
  12. 12.
    Desch CE, Magorien RD, Triffon DW, Blanford MF, Unverferth DV, Leier CV (1979) Development of pharmacodynamic tolerance to prazosin in congestive heart failure. Am J Cardiol 44: 1178–1182PubMedCrossRefGoogle Scholar
  13. 13.
    Elkayam U, Lejemtel TH, Mathur M, Ribner HS, Frishman WH, Strom J, Sonnenblick EH (1979) Marked early attenuation of hemodynamic effects of oral prazosin therapy in chronic congestive heart failure. Am J Cardiol 44: 540–545PubMedCrossRefGoogle Scholar
  14. 14.
    Eltze M (1979) Investigation on the mode of action of a new antihypertensive drug, urapidil, in the isolated rat vas deferens. Eur J Pharmacol 59: 1–9PubMedCrossRefGoogle Scholar
  15. 15.
    Franciosa JA (1984) Exercise testing in chronic congestive heart failure. Am J Cardiol 53: 1447–1450PubMedCrossRefGoogle Scholar
  16. 16.
    Franciosa JA, Dunkman B, Leddy CL (1984) Hemodynamic effects of vasodilators and longterm response in heart failure. JACC 6: 1521–1530Google Scholar
  17. 17.
    Franke N, Schmucker P, van Ackern K, Reichert B (1980) Antihypertensive Therapie mit Urapidil während der Narkose. Therapiewoche 30: 880–886Google Scholar
  18. 18.
    Freis ED (1984) Preload and afterload reduction in treating congestive heart failure. J Cardiovasc Pharmac 6: 895–902Google Scholar
  19. 19.
    Furberg CD, Yusuf S, Thom TJ (1984) Potential for altering the natural history of congestive heart failure: Need for large clinical trials. Am J Cardiol 55: 45A-47ACrossRefGoogle Scholar
  20. 20.
    Gless K-H, Gram N, Helmstädter V (1978) Die Wirkung von intravenös appliziertem Urapidil auf den Blutdruck bei Patienten mit krisenhaft erhöhtem Blutdruck. Therapiewoche 28: 6266–6270Google Scholar
  21. 21.
    Graham RM (1984) Selective alphai-adrenergic antagonists: Therapeutically relevant antihypertensive agents. Am J Cardiol 53: 16A-20APubMedCrossRefGoogle Scholar
  22. 22.
    Harper RW, Claxton H, Anderson S, Pitt A (1980) The acute and chronic haemodynamic effects of prazosin in severe congestive heart failure. Med J Aust 2 (Suppl): 36–38PubMedGoogle Scholar
  23. 23.
    Higginbotham M, Morris K, Coleman RE, Cobb FR (1982) Is long-term ambulatory therapy with prazosin effective in chronic heart failure? Circulation 66 (Suppl II): 11–210Google Scholar
  24. 24.
    Kern MJ, Horowitz JD, Ganz P, Gaspar J, Colucci WS, Lorell BH, Barry WH, Mudge GH (1985) Attenuation of coronary vascular resistance by selective alpha1-adrenergic blockade in patients with coronary artery disease. J Am Coll Cardiol 5: 840–846PubMedCrossRefGoogle Scholar
  25. 25.
    Kobrin I, Gallo A, Pergram BL, Frohlich ED (1984) Urapidil in normotensive and spontaneously hypertensive rats: The effects on systemic and regional hemodynamics and cardiac mass. J Hypertens 2: 317–320PubMedCrossRefGoogle Scholar
  26. 26.
    Kobrin I, Gallo A, Kumar A, Pegram BL, Frohlich ED (1984) Immediate hemodynamic changes produced by urapidil in normotensive and spontaneously hypertensive rats. Clin Exp Hypertens A6: 685–697CrossRefGoogle Scholar
  27. 27.
    Kobrin I, Amodeo C, Ventura HO, meserli FH, Fröhlich ED (1985) immediate hemodynamic effects of urapidil in patients with essential hypertension. Am J Cardiol 55: 722–725PubMedCrossRefGoogle Scholar
  28. 28.
    Kuhn H, Boch H, Lösse B (1981) Wirkung einer chronischen Verabreichung von Prazosin bei Patienten mit kongestiver Kardiomyopathie. Z Kardiol 70: 501–507PubMedGoogle Scholar
  29. 29.
    Langer SZ (1981) Presynaptic regulation of the release of catecholamines. Pharmacol Rev 32: 337–362Google Scholar
  30. 30.
    Levine TB (1985) Role of Vasodilators in the Treatment of Congestive Heart Failure. Am J Cardiol 55: 32A-35APubMedCrossRefGoogle Scholar
  31. 31.
    Markham RV, Corbett JR, Gilmore A, Pettinger WA, Firth BG (1983) Efficacy of prazosin in the management of chronic congestive heart failure: A 6-month randomized, double-blind, placebo-controlled study. Am J Cardiol 51: 1346–1352PubMedCrossRefGoogle Scholar
  32. 32.
    Mason DT (1978) Ventricular afterload reduction in management of congestive heart failure - A rational new concept that has rapidly come of age by vasodilator drugs. Clin Cardiol 1: 55–59PubMedGoogle Scholar
  33. 33.
    McFate-Smith W (1985) Epidemiology of congestive heart failure. Am J Cardiol 55: 3A-8ACrossRefGoogle Scholar
  34. 34.
    McMahon FG (1978) Management of essential hypertension. Futura, Mount Kisco NYGoogle Scholar
  35. 35.
    Nicholis DP, Harron DWG, Shanks RG (1981) Acute and chronic cardiovascular effects of indo- ramin and prazosin in normal man. Br J Clin Pharmacol 6: 61S-66SGoogle Scholar
  36. 36.
    Packer M, Meller J, Gorlin R, Herman MV (1979) Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure. Circulation 59: 531–539PubMedGoogle Scholar
  37. 37.
    Packer M, Meller J, Medina N, Yushak M, Gorlin R (1982) Serial hemodynamic studies indicate that early tolerance to prazosin in heart failure is not reversible (abstr). Circulation 66 (Suppl II): 11–210Google Scholar
  38. 38.
    Packer M (1983) Vasodilator and inotropic therapy for severe chronic heart failure: Passion and scepticism. JACC 2: 841–852PubMedGoogle Scholar
  39. 39.
    Rasmussen K (1982) Hemodynamic effects of alpha receptor blockade during acute administration and chronic treatment. Acta Med Scand (Suppl) 665: 83–85Google Scholar
  40. 40.
    Reiterer W (1981) Der Akuteffekt von Urapidil (i.v.) auf die Belastungshämodynamik bei Hypertonikern mit Linksherzinsuffizienz. In: Kaufmann W, Bruckschen EG (Hrsg) 1. Urapidil- Symposium, 20.-21.11.1981. Excerpta Medica, Amsterdam Oxford Princeton, S 166–178Google Scholar
  41. 41.
    Robertson RM, Bernard YD, Carr RK, Robertson D (1983) Alpha-adrenergic blockade in vasotonic angina: Lack of efficacy of specific alpha-1 receptor blockade with prazosin. J Am Coll Cardiol 2: 1146–1150PubMedCrossRefGoogle Scholar
  42. 42.
    Rouleau J-L, Warnica JW, Burgess JH (1981) Prazosin and congestive heart failure: Short- and long-term therapy. Am J Med 71: 147–152PubMedCrossRefGoogle Scholar
  43. 43.
    Schoetensack W, Bischler P, Dittmann EC, Steinijans V (1977) Studies on the influence of the antihypertensive drug urapidil on blood circulation and its regulation in animal experiments. Arzneimittelforsch 27: 1908–1919PubMedGoogle Scholar
  44. 44.
    Schoetensack W, Bruckschen EG, Zech K (1983) Urapidil. In: Scriabine A (ed) New drugs annual: Cardiovascular drugs. Raven, New York, pp 19–48Google Scholar
  45. 45.
    Schuster P (1981) Einsatz des Antihypertonikums Ebrantil bei Hochdruckkrisen. Klinikarzt 10: 202–211Google Scholar
  46. 46.
    Silber S, Schwaiger M, Klein U, Rudolph W (1980) Quantitative Beurteilung der linksventrikulären Funktion mit der Radionuklid-Ventrikulographie. Herz 5: 146–158PubMedGoogle Scholar
  47. 47.
    Silber S, Krause H, Garner C, Theisen K, Jahrmärker H (1983) Anti-Ischemic effects of an 80-mg tablet of isosorbide dinitrate in sustained-release form before and after 2 weeks treatment with 80mg once daily or twice daily. Z Kardiol 72 (Suppl 3): 211–217PubMedGoogle Scholar
  48. 48.
    van Zwieten PA (1984) Mechanism of antihypertensive action of urapidil in animals. Urapidil workshop, Gottlieben, 5th-6th JulyGoogle Scholar
  49. 49.
    Weber KT, Kinasewitz GT, West JS, Janicki JS, Reichek N, Fishman AP (1980) Long-term vasodilator therapy with trimazosin in chronic cardiac failure. N Eng J Med 303: 242–250CrossRefGoogle Scholar
  50. 50.
    Wießmann K-J, Münninghoff J, Krüger C (1983) Antihypertensive Therapie mit Urapidil bei Patienten mit obstruktiven Lungenerkrankungen. Fortschr Med 101: 291–294PubMedGoogle Scholar
  51. 51.
    Wilson JR, Martin JL, Schwartz D, Ferraro N (1984) Exercise intolerance in patients with chronic heart failure: Role of impaired nutritive flow to skeletal muscle. Circulation 69: 1079–1087PubMedCrossRefGoogle Scholar
  52. 52.
    Winniford MD, Filipchuk N, Hillis LD (1983) Alpha-adrenergic blockade for variant anginga: A long term, double-blind, randomized trial. Circulation 67: 1185–1188PubMedCrossRefGoogle Scholar
  53. 53.
    Zähringer J, Klepzig M, Greif J, Ludwig B, Strauer B (1984) Therapie der hypertensiven Krise mit Urapidil. Fortschr Med 102: 624–628PubMedGoogle Scholar
  54. 54.
    Zech K, Sturm E, Steinijans V (1981) Pharmakokinetik und Metabolismus von Urapidil bei Tier und Mensch. In: Kaufmann W, Bruckschen EG (Hrsg) 1. Urapidil-Symposium, 20–21.11.1981, Bad Kreuznach. Excerpta Medica, Amsterdam Oxford Princeton, S 50–64Google Scholar
  55. 55.
    Zelis R, Flaim SF, Moskowitz RM, Nellis SH (1979) How much can we expect from vasodilator therapy in congestive heart failure? Circulation 59: 1092–1097PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • S. Silber
    • 1
  • F. Hany
  • M. Weber
  • K. Theisen
  • H. Jahrmärker
  1. 1.HerzkatheterlaborMedizinische Klinik Innenstadt der UniversitätMünchen 2Germany

Personalised recommendations